A dramatic legal battle between tech giant Apple and medical technology innovator Masimo has reached a critical juncture, with a U.S. jury ordering Apple to pay a whopping $634 million in a patent infringement case. This decision, delivered on Friday, November 16, 2025, has sent shockwaves through the industry and sparked intense debate.
At the heart of the dispute are features in Apple's iconic smartwatch, the Apple Watch, which the jury found to infringe on Masimo's patent for blood oxygen monitoring technology. This verdict is just the latest chapter in a long-running legal saga that has pitted these two companies against each other in a battle for intellectual property rights.
But here's where it gets controversial: Apple has vehemently disagreed with the jury's decision and has announced plans to appeal. They argue that Masimo has a history of bringing similar cases, and that many of the patents previously raised were deemed invalid. Furthermore, Apple points out that the patent in question expired in 2022 and relates to older patient-monitoring technology.
For Masimo, this ruling is a significant victory in their fight to protect their innovations. The company has been locked in a complex legal conflict with Apple, including accusations that Apple hired Masimo employees and incorporated their pulse-oximetry expertise without permission.
The dispute has had far-reaching consequences, with regulatory bodies stepping in. In 2023, the U.S. International Trade Commission blocked imports of Apple's Series 9 and Ultra 2 watches, finding that they used technology covered by Masimo's patents. Apple responded by removing the blood-oxygen feature and later introduced an updated version, which received clearance from U.S. Customs and Border Protection.
However, the legal battle is far from over. On Friday, the ITC agreed to review whether Apple's updated watches still fall under the import restrictions. Masimo has also filed a lawsuit against Customs over their earlier decision, while Apple continues to challenge the import ban at the federal appellate level.
The companies have faced a mixed bag of outcomes in other courts as well. A trade-secret case brought by Masimo in California ended in a mistrial in 2023, while Apple secured a $250 award in Delaware last year in a dispute over design patents.
This ongoing legal battle highlights the complex nature of intellectual property rights and the high stakes involved in the tech industry. As the case continues to unfold, it will be interesting to see how these two powerful companies navigate the legal landscape and what impact this has on the future of wearable technology.
So, what do you think? Is this a fair decision, or is Apple being unfairly targeted? We'd love to hear your thoughts in the comments below!
